BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2023 10:42:35 AM | Browse: 200 | Download: 371
Publication Name World Journal of Experimental Medicine
Manuscript ID 85302
Country Italy
2023-04-21 09:50
Peer-Review Started
2023-04-21 09:52
To Make the First Decision
Return for Revision
2023-05-15 08:38
2023-05-16 14:09
Second Decision
2023-06-16 02:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2023-06-16 08:41
Articles in Press
2023-06-16 08:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
2023-06-13 03:58
Typeset the Manuscript
2023-08-25 02:57
Publish the Manuscript Online
2023-09-15 10:42
ISSN 2220-315x (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Ophthalmology
Manuscript Type Letter to the Editor
Article Title Ophthalmologic implications to consider when using hydroxychloroquine to treat COVID-19 and induced arthritis
Manuscript Source Invited Manuscript
All Author List Marco Zeppieri
Author(s) ORCID Number
Marco Zeppieri http://orcid.org/0000-0003-0999-5545
Funding Agency and Grant Number
Corresponding Author Marco Zeppieri, BSc, MD, PhD, Doctor, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy. markzeppieri@hotmail.com
Key Words COVID-19; Hydroxychloroquine; SARS-CoV-2; Retinopathy; Maculopathy; Post-COVID-19 arthritis
Core Tip Hydroxychloroquine (HCQ) is typically considered when treating rheumatic and autoimmune diseases. It has been currently considered to help treat symptoms of coronavirus disease 2019 and to help alleviate several clinical manifestations after infection. In this letter, several ophthalmological implications that should be taken into consideration when using this drug are discussed. While the drug may be beneficial in treating symptoms, ophthalmological manifestations can be of clinical importance. Proper diagnoses, periodic testing, and correct management of patients in chronic treatment with HCQ can ensure that any potential ophthalmological side effects are minimized.
Publish Date 2023-09-15 10:42
Citation Zeppieri M. Ophthalmologic implications to consider when using hydroxychloroquine to treat COVID-19 and induced arthritis. World J Exp Med 2023; 13(4): 95-98
URL https://www.wjgnet.com/2220-315x/full/v13/i4/95.htm
DOI https://dx.doi.org/10.5493/wjem.v13.i4.95
Full Article (PDF) WJEM-13-95-with-cover.pdf
Full Article (Word) WJEM-13-95.docx
Manuscript File 85302_Auto_Edited-JJW-WangTQ-JLW.docx
Answering Reviewers 85302-Answering reviewers.pdf
Audio Core Tip 85302-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 85302-Conflict-of-interest statement.pdf
Copyright License Agreement 85302-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 85302-Language certificate.pdf
Peer-review Report 85302-Peer-review(s).pdf
Scientific Misconduct Check 85302-Bing-Wang JJ-2.png
Scientific Editor Work List 85302-Scientific editor work list.pdf
CrossCheck Report 85302-CrossCheck report.pdf